Invivo Partners, member of CataloniaBio & HealthTech, is preparing the launch of its latest fund, Invivo Ventures III, with a target volume of €100 million. This new fund underscores Invivo Partners commitment to revolutionizing the life sciences sector, particularly at the intersection of advanced therapies, synthetic biology, and artificial intelligence.
With the launch of this new fund, Invivo Partners is delighted to announce the promotion of Laura Rodríguez from Principal to Partner, following a robust tenure in venture capital. With a PhD in Biotechnology and a strong background in oncology gene therapy research, Laura has contributed to the advancement of the biotech sector through her work in tech transfer at the Vall d’Hebron Hospital Research Institute and as a board director for portfolio companies. Laura is committed to fostering the biotech ecosystem, actively engaging as a mentor, evaluator, and board director, contributing significantly to the innovation ecosystem.
The fund’s focus aligns with Invivo’s mission to support early-stage life science companies that are at the forefront of innovation. With most private investors and the backing of significant institutional investors, Invivo Ventures III is poised to make a substantial impact in the life sciences ecosystem.
«I am deeply honored by the promotion to Partner at such a pivotal moment for Invivo Partners. This opportunity to contribute to the building of new companies that push the boundaries of innovation in advanced therapies is a challenge I accept with both gratitude and eagerness. » said Laura Rodríguez, Partner.
Invivo Partners continues to be a beacon of innovation and progress in the venture capital landscape, especially in the early-stage life sciences sector. The firm’s track record of successful investments and its strategic focus on areas like synthetic biology and advanced therapies underscore its commitment to driving meaningful change and progress in healthcare.
Comments